Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 264 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Cavity Infection Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

NCT05447078
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Immulina TM, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 3 Interventional

A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems

NCT00002315
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Netivudine, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 7:02 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

NCT01273103
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
200mg [14C]- GSK2248761
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
30 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3

NCT01336699
View directory record Official record
Conditions
Shigella Infection
Interventions
Placebo, WRSs2, WRSs3
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01984684
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
delafloxacin, vancomycin, aztreonam
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Mobile, Alabama • Montgomery, Alabama • Anaheim, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jul 22, 2026, 7:02 AM EDT
No Longer Available No phase listed Expanded access

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

NCT00162227
View directory record Official record
Conditions
HIV Infection
Interventions
Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
3 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Effect of Improved Oral Hygiene to Prevent Pneumonia in Hospitalized Patients

NCT00123123
View directory record Official record
Conditions
Pneumonia
Interventions
chlorhexidine gluconate oral rinse (0.12%), placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Jul 22, 2026, 7:02 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

P Gingivalis Oral Infection, Intimamedia Thickening in Infants, Atherosclerosis

NCT03083444
View directory record Official record
Conditions
Tooth Eruption, Atherosclerosis
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Creighton University
Other
Eligibility
4 Months to 24 Months
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Results available

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

NCT00793793
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI201335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01595438
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sylmar, California • Royal Oak, Michigan • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 3 Interventional

Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02570490
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
sodium fusidate, linezolid
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
12 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
60
States / cities
Anaheim, California • Bakersfield, California • Buena Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Jul 22, 2026, 7:02 AM EDT
Terminated Phase 2 Interventional Results available

Asymptomatic Congenital CMV Treatment

NCT03301415
View directory record Official record
Conditions
Congenital Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 30 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 22, 2026, 7:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Mouthrinse on the Microbiome of the Oral Cavity and GI Tract

NCT05603650
View directory record Official record
Conditions
Oral Bacterial Infection, Oral Infection, Microbial Colonization, Viral Infection
Interventions
Lumineux Oral Essentials rinse, Listerine rinse
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

NCT04603924
View directory record Official record
Conditions
COVID-19
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Sheffield, Alabama • Irvine, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 22, 2026, 7:02 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

NCT05052996
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ISL, LEN, B/F/TAF, ISL/LEN FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Beverly Hills, California • Los Angeles, California • Newport Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 22, 2026, 7:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Antibiotic Bowel Preparation in Gynecologic Oncology Surgery

NCT05210556
View directory record Official record
Conditions
Surgical Site Infection, Surgical Complication, Gynecologic Cancer
Interventions
Diagnosed with Surgical Site Infection
Other
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
778 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS

NCT00000966
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Azithromycin, Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Worcester, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

NCT02027454
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744, GSK1265744 matching placebo, Moxifloxacin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Jul 22, 2026, 7:02 AM EDT
Recruiting No phase listed Observational

Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery

NCT06681935
View directory record Official record
Conditions
Oral Cancer
Interventions
Oral Cavity Reconstruction
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection

NCT04931004
View directory record Official record
Conditions
Covid19
Interventions
Mouthwash Product
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Not applicable Interventional

Oral Antibiotics After 2-Stage Revision for Infected Total Hip Arthroplasty and Total Knee Arthroplasty

NCT01760863
View directory record Official record
Conditions
Prosthesis-Related Infections
Interventions
Oral Antibiotics
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • Winfield, Illinois • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

NCT01371578
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Jul 22, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK706769/KALETRA Drug-drug Interaction Study

NCT00723775
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK706769 & KALETRA
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jul 22, 2026, 7:02 AM EDT